Imagine a world where medicine isn't one-size-fits-all, but tailored exactly to your unique genetic makeup. This initiative acts like a bridge, taking complex lab discoveries and turning them into actual treatments used in clinics. It ensures that the right patient gets the right drug at the right time by coordinating experts across Europe.
Medical treatments often fail because they are not tailored to individual genetic differences. There is a gap between laboratory discovery and the actual delivery of these treatments in sustainable healthcare systems.
A Strategic Research and Innovation Agenda (SRIA 2023) and a global platform for scientific dialogue. It also established Joint Transnational Calls (JTC) to fund specific target identification and validation projects.
If you are a drug developer dealing with high failure rates in clinical trials — this project developed a strategic research and innovation agenda that helps identify and validate targets. This ensures treatments are designed for specific patient subgroups, increasing the chance of success.
If you are a diagnostics provider dealing with fragmented market access — this project developed a global platform for strategic dialogue. This helps align your precision tools with the needs of healthcare providers and payers across 26 countries.
If you are a hospital network dealing with inefficient treatment protocols — this project developed demonstration projects to show how personalised medicine works in practice. This allows you to implement sustainable health systems that improve patient outcomes.
Based on available project data, specific pricing or costs are not mentioned as this is a funding and coordination partnership.
The project focuses on the full value continuum to move achievements from research to implementation in sustainable health systems, though specific industrial scale metrics are not provided.
Based on available project data, there is no specific mention of licensing terms; however, it results in public documents and publications to align the global platform.
The partnership is active from 2023-11-01 to 2033-10-31, indicating a long-term strategic rollout over a decade.
It reaches out to the 1+Million Genomes Initiative and the European Strategy Forum on Research Infrastructures (ESFRI) to ensure alignment with existing data and research systems.
The consortium is heavily weighted toward the public and research sectors, consisting of 59 partners from 26 countries. Notably, it contains 15 research organizations and 44 other entities, but 0 universities and 0 industry partners (0% industry ratio). This suggests the project is currently a high-level strategic and funding coordination body rather than a commercial development venture.
Contact DEUTSCHES ZENTRUM FUR LUFT - UND RAUMFAHRT EV for partnership inquiries.
Contact us to identify specific JTC funding opportunities within the EP PerMed portfolio.
